Weekly Retail Sales Tracker for I&I in Derm/GI - Week Ended May 8

Research evidence excerpt

Weekly Retail Sales Tracker for I&I in Derm/GI - Week Ended May 8

Quick Note

May 15, 2026 Biotechnology

Weekly Retail Sales Tracker for I&I in Derm/GI - Week Ended

Analysts May 8

David Nierengarten, Ph.D.

(415) 274-6862

David.Nierengarten@wedbush.com

Martin Fan, Ph.D. In this weekly report we provide updated IQVIA prescription data for select, FDA-

(213) 688-3404 approved branded I&I drugs for dermatology and GI indications distributed through

Martin.Fan@wedbush.com retail drug channels in the U.S. market only, through the Week Ended May 8. This

Dennis Pak report is meant to serve as a guide for evaluating trends in branded retail drug(415) 263-6647

Dennis.Pak@wedbush.com use in the US and should not be relied upon for definitive accuracy as a number of

dynamics may influence the reported numbers.

Key components of the report:

● Script Data by Select Drug Class: In this section we provide a summary of IQVIA

script data for select drugs organized by pertinent drug class or indication. Drug

classes or indications we’re currently tracking include:

■ IL-13 inhibitors

■ IL-17 inhibitors

■ IL-23 inhibitors

■ JAK inhibitors

■ S1P Receptor Modulators

■ TNFα inhibitors

● Drug Snapshots: This section provides a one-page snapshot of select FDA

approved drugs for solid tumors. Information includes basic identifying

information (manufacturer, drug target/mechanism, route of administration

and dosing schedule, approval history, drug label, and current monthly price),

as well as weekly retail channel sales estimates (TRx MBS Dollars), New (NRx),

Repeat (RRx) and Total (TRx) weekly script count, and Total (TRx) weekly unit

(i.e. pill/vial) counts.

Wedbush Securities does and seeks to do business with companies covered in its research

reports.